

10 March 2023

The Manager
ASX Compliance Pty Ltd
152-158 St Georges Terrace
PERTH WA 6000

ListingsCompliancePerth@asx.com.au.

Attention: Nicholas Mountain

Via email

Dear Sir,

I refer to your letter of 10 March 2023 and advise as follows, in response to the questions raised:

1. No.
2. N/A.
3. As previously announced the FDA mid-cycle review process is scheduled for completion in 1Q 2023. This is considered a significant milestone event, as it will provide written feedback from FDA if there are any significant review issues remaining for product approval. The Company is waiting to receive this communication from FDA.

The Company also notes the webinar conducted on 8 March 2023 providing new insights into competitive and market situation and opportunities to access patients through digital outreach in addition to traditional dermatology channels, for its Sofpironium Bromide product following primary research conducted by the independent research company, Triangle Insights Group.

The approaching milestone and recent presentation may be explanation for the recent interest and trading in the Company's shares.

4. The Company confirms it is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.
5. Confirmed

Yours sincerely



Simon Robertson
Company Secretary



10 March 2023

Reference: 70350

Mr Simon Robertson
Company Secretary
Botanix Pharmaceuticals Ltd

By email: simon@slrconsulting.com.au;

Dear Mr Robertson

Botanix Pharmaceuticals Ltd ('BOT'): Price - Query

ASX refers to the following:

- A. The change in the price of BOT's securities from an intraday low of \$0.082 to an intraday high of \$0.105 today; and
- B. The significant increase in the volume of BOT's securities traded today.

Request for information

In light of this, ASX asks BOT to respond separately to each of the following questions and requests for information:

- 1. Is BOT aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
- 2. If the answer to question 1 is "yes".
 - (a) Is BOT relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in BOT's securities would suggest to ASX that such information may have ceased to be confidential and therefore BOT may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
 - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
 - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
- 3. If the answer to question 1 is "no", is there any other explanation that BOT may have for the recent trading in its securities?
- 4. Please confirm that BOT is complying with the Listing Rules and, in particular, Listing Rule 3.1.
- 5. Please confirm that BOT's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of BOT with delegated authority from the board to respond to ASX on disclosure matters.

When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **2:30 PM AWST Friday, 10 March 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall

within the exceptions mentioned in Listing Rule 3.1A, BOT's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require BOT to request a trading halt immediately.

Your response should be sent to me by e-mail at **ListingsCompliancePerth@asx.com.au**. It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in BOT's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in BOT's securities under Listing Rule 17.3.

Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to BOT's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that BOT's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

Release of correspondence between ASX and entity

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Regards

Nicholas Mountain

Adviser, Listings Compliance